VistaGen Obtains US Patent for Novel Stem Cell Production Method

VistaGen Therapeutics (NASDAQ:VTGN) announced it received a patent from the U.S. Patent and Trademark Office (USPTO) covering their method for producing hematopoietic precursor stem cells.
As quoted in the press release:

VistaGen holds an exclusive license to this patent from the University Health Network (UHN).
The technology covered by the issued U.S. patent has the potential to impact both direct and supportive therapy for autoimmune disorders and cancer, with CAR-T cell applications, and foundational technology which may provide approaches for producing bone marrow stem cells for bone marrow transfusions.
Dr. Gordon Keller, Director of the McEwen Centre for Regenerative Medicine in Toronto, one of the world’s leading centers for stem cell and regenerative medicine research and part of the University Health Network (UHN), discovered the stem cell technology covered by this patent.

Click here to read the full press release.

Source: www.marketwired.com